FRESENIUS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | -.--% |
| 05-17 | What does the new atlas mean for the 'hospital jungle'? | DP |
| 05-17 | Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative | MT |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.35 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 17.11B | - | ||
| +19.28% | 84.56B | C+ | ||
| -26.95% | 72.41B | B- | ||
| +4.65% | 27.75B | C+ | ||
| -7.35% | 17.75B | B | ||
| +4.69% | 16.03B | A- | ||
| +8.14% | 13.72B | B- | ||
| +69.96% | 13.07B | C- | ||
| +6.59% | 12.91B | A- | ||
| +70.00% | 12.55B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FRE Stock
- 0OO9 Stock
- Ratings Fresenius
